论著
Dai Zhijun①;Wang Xijing①;Kang Huafeng①;Guan Haitao①;Liu Xiaoxu①;Song Lingqin①;Cheng Chong①;Ji Zongzheng②
2007, 9(1): 10-14.
Objective: To observe the efficacy and adverse reactions of Shenqifuzheng injection used in patients with breast cancer while receiving neoadjuvant chemotherapy. Methods: Clinical deta of 126 patients with local advanced breast cancer while receiving neoadjuvant chemtherapy was collected from January, 2000 to December, 2005. The 126 patients were divided randomizely into two groups: control group (61 cases) and study group (65 cases). The patients in the control group were administered with CEF regimen (CTX 500 mg/m2, d1, 8; EPI 50 mg/m2, d1, 8; 5-Fu 500 mg/m2, d1, 8). The patients in the study group were treated with CEF regimen plus Shenqifuzheng injection (intravenous infusion of 250 ml, once daily). The cycle of chemotherapy was 28 d, and total two cycles were performed for the two groups. The efficacy, the changes of T lymphocyte and NK cells, and the adverse reactions to neoadjuvant chemotherapy in the two groups were observed before and after the treatment. Results: The overall …更多effective rate of the study group and control group were 69.2% (45/65) and 49.2% (30/61) respectively, and the difference was statistically significant between the two groups (P<0.05). The T lymphocyte subsets and NK cells in the study group were elevated in varying degree in comparison with those in the control group, and the differences were significant (P<0.05). The common adverse reactions of the two groups were myelosuppression and gastrointestinal reactions, but the severity of the reactions of the study group were relative mild than that of the control group. Conclusion: Shenqifuzheng injection can elevate immune function of patients with advanced breast cancer while receiving neoadjuvant chemotherapy. It can also enhance the efficacy and decrease the adverse reactions to neoadjuvant chemotherapy